Carolyn E. Taylor, serving as a director at Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), executed a direct purchase of the company's common stock on June 12, 2026. The transaction involved the acquisition of 1,415 shares at a price of $10.55 per share, resulting in a total transaction value of $14,928. Following this acquisition, Ms. Taylor's direct holdings in Tonix Pharmaceuticals common stock increased to 1,833 shares.
Insider activity of this nature is closely monitored for signals regarding internal confidence and valuation perceptions. The purchase comes as TNXP shares trade at $11.35, representing a 64% decline over the past twelve months. Despite this price action, analysts maintain a strong buy consensus on the stock. According to InvestingPro analysis, TNXP appears undervalued at current levels based on its Fair Value assessment. The company maintains a healthy balance sheet with more cash than debt, though InvestingPro Tips highlight that the stock remains highly volatile. Investors can access 12 additional ProTips and comprehensive financial metrics on the platform.
Tonix Pharmaceuticals has also announced significant developments regarding its fibromyalgia treatment, TONMYA. The company reached an agreement with a second group purchasing organization, expanding commercial coverage to approximately 17 million additional U.S. lives, effective June 1, 2026. This brings the total coverage for TONMYA to around 52 million U.S. commercial lives, which accounts for 29% of the estimated 177 million commercial lives in the country. Previously, Tonix had secured coverage for 35 million lives through a prior agreement effective May 1.
Additionally, Tonix presented data on opioid use among fibromyalgia patients at the 2026 ASCP Annual Meeting. This study included data from 261,776 adult patients, providing insights into opioid use patterns. In another development, the company published phase 1 study results for TNX-1500, a drug being developed for organ transplant rejection and autoimmune diseases. These results were featured in the Journal of Clinical Immunology, following trials with 26 healthy adult volunteers. These recent developments highlight Tonix Pharmaceuticals' ongoing efforts in expanding treatment coverage and advancing its drug pipeline.